Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
StemCell Institute Inc. (7096.T)
Tokyo, JP
StemCell Institute Inc. provides specialized stem cell banking services throughout Japan. In addition to its core preservation activities, the company is deeply involved in the research and development of medical therapies that utilize stem cells, and it also offers banking solutions for blood vessel cells. Founded in 1999, StemCell Institute Inc. is headquartered in Tokyo, Japan, and operates as a subsidiary of Trim Medical Holdings Inc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.15% | -7.85% | -10.51% | -22.08% | -14.88% | -13.58% | -44.90% | -70.46% | -67.02% | -67.02% | -67.02% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+4.9% ★ Q1'26: +4.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-59.0% Q1'26: -79.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-0.2% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+7.2% ★ Q1'26: -2.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+17.1% ★ Q1'26: -8.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-1.4% ★ Q1'26: -2.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.32× ★ Q1'26: 3.99× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
1.78B
est: 1.76B (+1.3%)
|
2.09B
est: 2.12B (-1.4%)
|
2.48B
est: 2.57B (-3.5%)
|
2.68B
est: 2.74B (-2.2%)
|
2.87B
2.87B – 2.87B
+4.7% YoY
|
3.18B
3.18B – 3.18B
+10.8% YoY
|
3.80B
3.80B – 3.80B
+19.5% YoY
|
| EBITDA |
309.47M
est: 325.61M (-5.0%)
|
402.49M
est: 392.51M (+2.5%)
|
534.00M
est: 1.07B (-50.1%)
|
695.19M
est: 1.14B (-39.0%)
|
1.19B
1.19B – 1.19B
+4.7% YoY
|
1.32B
1.32B – 1.32B
+10.8% YoY
|
1.58B
1.58B – 1.58B
+19.5% YoY
|
| EBIT |
212.58M
est: 246.71M (-13.8%)
|
297.56M
est: 297.40M (+0.1%)
|
413.76M
est: 914.00M (-54.7%)
|
566.91M
est: 974.46M (-41.8%)
|
1.02B
1.02B – 1.02B
+4.7% YoY
|
1.13B
1.13B – 1.13B
+10.8% YoY
|
1.35B
1.35B – 1.35B
+19.5% YoY
|
| Net Income |
133.73M
est: 149.53M (-10.6%)
|
198.03M
est: 220.19M (-10.1%)
|
310.98M
est: 379.96M (-18.2%)
|
385.80M
est: 399.42M (-3.4%)
|
183.32M
183.32M – 183.32M
-54.1% YoY
|
203.81M
203.81M – 203.81M
+11.2% YoY
|
325.68M
325.68M – 325.68M
+59.8% YoY
|
| SGA |
875.00M
est: 881.63M (-0.8%)
|
1.03B
est: 1.06B (-3.5%)
|
1.14B
est: 1.29B (-11.3%)
|
1.27B
est: 1.37B (-7.3%)
|
1.44B
1.44B – 1.44B
+4.7% YoY
|
1.59B
1.59B – 1.59B
+10.8% YoY
|
1.90B
1.90B – 1.90B
+19.5% YoY
|
| EPS |
13.20
est: 14.60 (-9.6%)
|
19.33
est: 21.50 (-10.1%)
|
30.25
est: 37.10 (-18.5%)
|
37.67
est: 39.00 (-3.4%)
|
17.90
17.90 – 17.90
-54.1% YoY
|
19.90
19.90 – 19.90
+11.2% YoY
|
31.80
31.80 – 31.80
+59.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-01 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hideaki Sato | Executive Officer | — | — |
| Mamoru Ishii | Executive Officer | — | — |
| Satoshi Tsuchiyama | Executive Officer | — | — |
| Takafumi Shimizu | Chairman & President | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7096.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
